Crupi Armando, Lanzetti Jacopo, Todaro Daniela, Pera Francesco, Erovigni Francesco Maria
Department of Oral Rehabilitation and Maxillofacial Prosthesis, Dental School, University of Turin, Via Nizza 230, 10126 Turin, Italy.
Int J Mol Sci. 2025 Apr 11;26(8):3618. doi: 10.3390/ijms26083618.
The interaction between antiresorptive medication and dental implant procedures remains a subject of concern complicating the decision-making process for clinicians. The aim of the study is to conduct a literature review on the relationship between dental implant placement and the incidence of osteonecrosis of the jaw (ONJ) in patients receiving antiresorptive drugs. The systematic review relied on the PRISMA statement using the PICO tool. The literature search was performed using PubMed, EBSCOhost and Scopus for RCTs, controlled clinical trials and cohort studies. The choice of reference studies was made in a blind process with a 100% agreement rate. For all included studies, quality assessment was performed. The research led to the selection of 608 results. Only five studies were included in the review. Three of the included studies were judged as having a low risk of bias. Dental implants may not be linked to a higher risk of osteonecrosis of the jaw in patients taking low-dose bone-modifying agents. The long-term survival of implants in osteoporotic patients taking oral antiresorptive medication was similar to that in a healthy population and significantly higher than in untreated controls.
抗吸收药物与牙种植手术之间的相互作用仍是一个备受关注的问题,这使得临床医生在做决策时变得复杂。本研究的目的是对接受抗吸收药物治疗的患者牙种植体植入与颌骨坏死(ONJ)发生率之间的关系进行文献综述。该系统评价依据使用PICO工具的PRISMA声明进行。文献检索通过PubMed、EBSCOhost和Scopus进行,检索随机对照试验、对照临床试验和队列研究。参考文献研究的选择过程是盲选,一致率达100%。对所有纳入研究进行质量评估。该研究筛选出608项结果。综述仅纳入5项研究。其中3项纳入研究被判定偏倚风险较低。对于服用低剂量骨改良剂的患者,牙种植体可能与颌骨坏死风险升高无关。服用口服抗吸收药物的骨质疏松患者中种植体的长期存留率与健康人群相似,且显著高于未治疗的对照组。